In a guinea pig model, high doses of antiplatelet antibody bind to both platelets and megakaryocytes, whereas low doses bind only to platelets, suggesting dose-dependent differential binding.
These guinea pig results should not yet change clinical practice; hypothesis-generating for dose-dependent megakaryocyte effects in thrombocytopenia.
Flow cytometric analysis was done for the detection of rabbit anti-guinea pig platelet antibody on guinea pig platelets and megakaryocytes. Antiserum, absorbed by guinea pig erythrocytes, was intraperitoneally administered.Antibody-binding to platelets was strongly detected 1.5 and 3h after injection of 2ml/kg body weight of antibody followed by severe thrombocytopenia after 3h. Apparent antibody-binding to megakaryocytes obtained by centrifugal elutriation was detected 12 and 36h later. The number of megakaryocytes was not changed. Injection of 0.4ml/kg of antibody caused mild thrombocytopenia with manifest antibody-binding to platelets, and no apparent binding to megakaryocytes.These findings suggest that platelet-associated antibody caused thrombocytopenia and that serum antibody reached to megakaryocytes. But small amount of antibody had different attitude on antibody-binding to platelets and megakaryocytes.
No takes yet. Share an insight, caveat, or question.
Saigo et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: